Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
The last 2 days have been like a coiled spring getting wound up tighter and tighter. It will suddenly snap higher and be in the £ before you know it.
Just for the record I'm talking my book, so please don't base any investment decisions on my post.
DYOR
Nothing has changed, apart from the day traders jumping ship as the upward momentum has subsided. Might drift a little lower in the meantime, but they'll be fully invigorated on new news. At the end of the day they have a product that's been tested and is available to buy. Patience is the golden rule with this one
In my eyes this is turning out to be a healthy correction. I'm not sure of the posts earlier of the MM sucking in unsuspecting punters, if the share was on a downward trajectory they would have a point, but this is setting new highs on a weekly basis and has changed today for that to continue
Lots of negative views on here this morning. I like to address each individually. Any new cash call will be at a premium as have the others. If they are raising funds to meet excess demand for their product surely that's a good thing as return on money will be instant. I still think this has more to go, short term there is a gap at around 56.8p going back to July 21 that needs filling.
Lots of posts around the cost and would the NHS pay. At the moment if you've had an MRI which in itself is expensive and it proves to be fine, they'll then want to monitor you over the next year by having a blood test every 3 months. If this could all be replaced by a simple test that would save the NHS millions. It's just more cost effective in the long run
Seems to be a lot of old articles being banded around this evening with none of the products associated seeing the light of day. If one is on the market id be very interested to see a link.
OBD product is available to order in America now, the high price really isn't an issue over there as it's claimed on the patients medical insurance.
They are certainly powering ahead on this. Must have known the results would be positive and lined up their ducks accordingly.
Question now is what is a realistic sp value and what 3rd parties are on the sidelines itching to join the party. How many potential investors are out there that haven't even heard about their success. Admitedly there are potential pitfalls along the way, but they seem to have done their homework and all the news is positive. The share price could well overshoot true value but in my opinion we are not even close. Buy what you are prepared to loose, and come back in a couple of months, you'll be estatic
Actually the placeing in August was at a premium to the share price, The shares were trading at around 11p and the issue was at 12p.
One the bods owns a company that has at 14% stake in the company. Clearly they knew they were onto something hence the premium and bods having skin in the game.
Just like Oxford Bio this week, why go through all the pain when you can just join the party as it gets going
Stalicla have their fingers in lots of pies. Similar to Evgen trying to apply their product to lots of different areas hoping one works. Four areas of concern
1. They've pretty much done the same thing they did with Juv, keep moving the payment date forward with no explanation.
2. Still no bod participation. There was absolutely no reason for them not to buy in on the last share dilution but they chose not to. Happy to encourage everyone else to do so though
3. Huws shocking track record as a company director. Just look him up on company house.
4. A share placement in the spring will further dilute shareholder value.
All doesn't bode well in my eyes.
Just over half the shares are available to be traded. This in itself keeps these up.
Vulpes Investment Management Pte Ltd.
14.06 %
Unicorn Asset Management Ltd.
8.313 %
Seneca Partners
5.723 %
Investec Wealth & Investment Ltd.
3.618 %
Alexandre Akoulitchev
3.264 %
University of Oxford
2.830 %
Aroul Ramadass
2.595 %
Chelverton Asset Management Ltd.
2.472 %
Armistice Capital LLC
2.437 %
GL Capital Group
2.317 %
It's always difficult to get a true market value, but if we look at what we know
Analysts at Shore Capital said: “There are approximately 47 million men in the relevant 50-80 age range in the key US market and 25 million PSA tests per year, and a further 10 million men in the UK. The medical need for an improved test is clear.
I saw a video posted on here where the company stated the product would cost around £100 each.
57,000,000 x £100 = 5.7 billion.
Divide that by the share issue you're looking at £41 a share. Admittedly this is a very simple and quite frankly overly optimistic analysis, but it gives us some indication.
Trick - So surely you should be grateful that I've single handedly managed to lower the price. if you're so convinced it's a great opportunity to fill your boots. Now OBD is a completely different kettle of fish, they now have a proven product that will truly transform Prostate cancer diagnosis. Just wait until the Media get hold of this, they're desperate for a British success story and this is it.
May at worst drift a little lower but this is transformational news and you'll soon have more buyers stepping in. Just wait until it's picked up by the main media. They are desperate for a British success story and this is it
A thank you to FormallyeasyP for bringing this to my attention this morning. I had a Prostrate scare earlier in the year, elevated PSA reading. Options were either an autopsy to remove a sample which reading up on was not a pleasant experience or an MRI scan. This test will save the NHS millions in man/women hours and free up MRI machines and hospital beds. Now let's magnify this on a world scale and this company's share price could go through the stratosphere.
Tricky - there are so many red flags with this. Take the Juv payment that never happened, on initial news release the payout was due in 2022, and then kept moving it forward. They've done exactly the same with Stalicla, initially it was due end of December 2023, now they've moved that to Dec 24 again with no explanation. This will go the same way, hence the share price where it is.
Also saves the NHS money and time having to undertake MRI scans to get a more accurate picture. Looks interesting